Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

OKYO Pharma Limited - Ordinary Shares (NQ: OKYO )

1.500 UNCHANGED
Streaming Delayed Price Updated: 9:30 AM EDT, May 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,006
Open 1.500
Bid (Size) 1.480 (1)
Ask (Size) 1.500 (178)
Prev. Close 1.500
Today's Range 1.500 - 1.500
52wk Range 0.9201 - 3.250
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
From OKYO Pharma LTD
Via GlobeNewswire

Performance

YTD
-22.68%
-22.68%
1 Month
+2.04%
+2.04%
3 Month
+1.35%
+1.35%
6 Month
-6.25%
-6.25%
1 Year
-3.23%
-3.23%

More News

Read More
OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
From OKYO Pharma LTD
Via GlobeNewswire
Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study
Via Benzinga
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
From OKYO Pharma LTD
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
From OKYO Pharma LTD
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
From OKYO Pharma LTD
Via GlobeNewswire
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
From OKYO Pharma LTD
Via GlobeNewswire
Dow Rebounds, Still Below Fair Value
Via Talk Markets
Topics Stocks
Exposures US Equities
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
From OKYO Pharma LTD
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Dry Eye Disease Affects Around 50M Americans, OKYO Pharma's Candidate Shows Safety In Mid-Stage Study
Via Benzinga
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.